Entod Pharmaceuticals, a prominent player in the nation’s eye care industry, has demonstrated impressive market growth, reinforcing its strong stance in both ophthalmology and ENT (ear, nose, throat) treatment sectors.
According to the most recent market insights from September 2024 by IQVIA, the ophthalmological and otological fields faced considerable challenges, managing to grow by merely 1% annually. In contrast, Entod Pharmaceuticals bucked this trend with an exceptional 8% growth, highlighting its robust market presence and resilience.
In October, data from Pharmarack AWACS reported a revival in the sector, reflected by a strong 9.5% value growth. Nevertheless, Entod Pharmaceuticals exceeded this with an extraordinary 22% growth, more than doubling the industry’s average.
“Our remarkable market performance underscores Entod’s dedication to providing innovative and accessible eye and ENT care solutions. Even amid widespread industry challenges, our commitment to research-driven treatments, expanding into underserved regions, and targeted campaigns for eye health awareness have been vital to our success. By tackling critical issues like childhood myopia and glaucoma through cutting-edge treatments and awareness projects, we are not just setting high market standards but also enhancing the standard of eye care across India and globally,” stated Nikkhil K Masurkar, CEO of Entod Pharmaceuticals.
Milton Jose, the company’s vice president of sales, credits this success to several factors, including improved performance in North India, strong sales fueled by groundbreaking treatments for chronic eye ailments, and strategic efforts to enhance productivity per medical representative. He also emphasized the expanded sales reach, stretching from urban centers to rural areas, and the introduction of new prescription drugs as key factors driving the company’s ongoing momentum.
Entod Pharmaceuticals proudly employs over 1,200 medical representatives who advocate for more than 300 medicinal products within India. The company has a global reach across 67 countries, with its international business growing at a remarkable 60% annually, and an advanced R&D pipeline focused on therapeutic innovations for childhood myopia, glaucoma, corneal conditions, and retinal disorders.